Equity
-€151,991
Debts exceed assets in financial year 2025.
ODUXIO
Lifetime
14 annual accounts with figures on one time axispeak €152,993 (2019)
-€37,972▼ €13,198
lowest -€187,273 (2012)
-€83,884▼ €8,577
peak €7,199 (2023)
-€151,991▼ €83,884
€285,562▼ 17.0%
peak 3 FTE (2012)
-not published
Board2 names since 2011
1 director
Documentsfilings and deeds
21-08-202621 days late
2025micro format
Gross margin from -€24,774 to -€37,972Loss of €83,884Equity from -€68,108 to -€151,991Debts from €344,052 to €285,562Cash from €5,580 to €2,263
Key points
from the 2025 annual accountsLosses
-€159,190 in two years
The 2024 and 2025 financial years closed with a loss. 2025 was the heaviest.
Debts
€285,562 214% of the balance sheet
Suppliers 3%Taxes and wages 0%Other 97%
Of this, €195,463 falls due within a year.
Filings
14 annual accounts since 2012
Three of the last ten came late. The 2017 accounts came latest: 27 days after the end of the period.
At the same address
220 companies
Position in the sector
-€151,991
Less equity than 95% of companies in research and development. Sector median €113,589 · 668 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 6,920 companies had the same profile as ODUXIO has now. Each dot stands for 18 companies, two years later.
85.3%
were still trading
8.3%
stopped another way
5.8%
went bankrupt
Another 0.7% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,920 companies, not a prediction for ODUXIO. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0840141744
Registered office moved from Wavre to Ixeiles
New registered office: Bruxelies, au 143/4 avenue Lousie, 1050 Ixeiles · Previous registered office: Wavre, 6H Avenue Pasteur (1300 Wavre) · Resignation: (manager and director) · General meeting of 01-08-2024 · Gazette deed
Merger: T.K.T ZOUTE takes over HAULIGA
Company renamed from T.K.T ZOUTE to ODUXIO · Resignation: (director) · Appointment: (administrateur unique et non statutaire) · General meeting of 23-05-2023 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| ODUXIO Ixelles | €133,570 | -€37,972 | -113.8% | - |
| PXLENCE Ghent | €147,731 | -€72,071 | -51.3% | - |
| PROMISC Ramillies | €82,953 | -€3,459 | -6.8% | - |
| MDSH Ixelles | €92,229 | €4,192 | 89.3% | - |
| Dr. D. FRANCOIS PHOTOMED Molenbeek-Saint-Jean | €291,936 | -€15,906 | 45.8% | - |
| HANS DE VILDER - CLINICAL RESEARCH CONSULTANCY Genk | €267,868 | €2,348 | 2.9% | - |
| OCTIMET Oncology Geel | €252,753 | -€16,540 | 96.4% | - |
These companies have the same main activity as ODUXIO: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €83,000 and €292,000, founded between 2007 and 2016.
Official details
Source: KBO- Status
- Active since 11-10-2011Normal situation
- Registered office
- 221 active companies are registered at this address6 started in the 12 months before. Source: KBO register, as of 14 November 2026.
- Activity
- Research and development on biotechnologyNACE 72101and 2 others
- Establishment unit
- 2.205.109.6111050 Ixelles, since 16-12-2011
- Financial year end
- 31 December
- Peppol
- Reachable since 28-06-2025
Insights on ODUXIO
ODUXIO files the micro format. That format states no turnover. The gross margin rose from -€69,847 in 2012 to -€37,972 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about ODUXIO
- What is the company number of ODUXIO?
- The company number of ODUXIO is 0840.141.744. The VAT number is the same number with BE in front: BE 0840.141.744.
- Where is ODUXIO based?
- The registered office is at Louizalaan 143, 1050 Ixelles.Company details
- What does ODUXIO do?
- According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
- What is the legal form of ODUXIO?
- ODUXIO is a private limited company (BV).
- When was ODUXIO founded?
- ODUXIO was founded on 11-10-2011.
- Is ODUXIO still active?
- Yes, ODUXIO is an active enterprise in the KBO register.
- What is the turnover of ODUXIO?
- The annual accounts for financial year 2025 state no turnover.Financials
- Is ODUXIO profitable?
- In financial year 2025, ODUXIO made a loss of €83,884.
- Where can I find the annual accounts of ODUXIO?
- ODUXIO filed 14 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ODUXIO due?
- ODUXIO must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.